Icosavax, Inc.
DelistedCIK 1786255fmd_11GFPZ3HVW3TFMRH1YSP0G0T13Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Sep 30, 2023, 15 periods
| Line item | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
| Total revenues | 2 | 8 | 1 |
| Net interest income | – | (0) | 3 |
| Research and development | 18 | 39 | 65 |
| Total operating expenses | 20 | 74 | 96 |
| Operating income | (19) | (66) | (95) |
| Interest expense | 0 | 0 | – |
| Interest and investment income | 0 | 0 | – |
| Other non-operating income (expense) | (0) | (1) | 3 |
| Net income | (19) | (67) | (92) |